Proffered Paper - Developmental therapeutics
LINK to STREAM (needs an ESMO registration)
524O - Initial results of a phase I study of MK-4830, a first-in-class anti–immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced solid tumours
The abstract concludes: This first-in-class MK-4830 antibody targeting ILT4 given as monotherapy and in combination with pembro was well tolerated and showed dose-related evidence of target engagement. Durable responses were observed with both MK-4830 alone and with MK-4830 + pembro in heavily pretreated pts, 5 of whom progressed on prior anti–PD-1 therapies. These initial data support the further development of MK-4830 + pembro for pts with advanced solid tumors.
Read also ESMO's Daily Reporter News:
525O - A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
The abstract concludes: PRS-343 is the first 4-1BB bispecific to demonstrate encouraging evidence of safety and clinical benefit with a correlative PD effect. Based on these data, a phase II trial in gastric/GEJ cancer has been planned in combination with ramucirumab and paclitaxel.
526O - High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours
The abstract concludes: We report the first clinical trial assessing aPD1 in POLE mutated MMRp tumours. Nivolumab activity appears promising in edPOLE mutated MMRp advanced cancer pts but activity is limited to pathogenic mutations, underlining the need for individual mutational functional assessment by a molecular tumour board. We will include the tumour evaluation of the last 5 additional patients at the ESMO 2020 Virtual Congress.
527O - CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study
The abstract concludes: CC-90010 was well tolerated and showed antitumor activity in heavily pretreated pts with advanced malignancies. The long t1/2 and favorable PD profile improved tolerability and enabled less frequent dosing. These results support further evaluation of CC-90010 in STs and R/R DLBCL.
528O - CC-90011 in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study
The abstract concludes: CC-90011 was well tolerated with favorable PK/PD profiles. Promising antitumor activity was observed in pts with NENs and R/R NHL.